Winona offers both a progesterone capsule and a body cream combining estrogen with progesterone. Its cream is presented as a convenient way to deliver both hormones together. For someone trying to understand the purpose of an added medicine, that convenience creates a separate question: what supports the protective role claimed for this particular preparation?

Reviewed September 29, 2026, the public product pages and FAQ establish real treatment offers. This assessment distinguishes their ingredients, claims and subscription terms. It does not verify a dispensed product or accept a cream as an appropriate replacement for a capsule.

Editorial illustration: an open reference book, a magnifying glass and a document.
Winona menopause progesterone review: a combined cream needs its own evidence — follow the source behind a claim as well as the advertised description.

Two product records should remain two product records

The capsule page names oral progesterone and declares inactive ingredients including peanut oil and gelatin. The combination cream instead lists estradiol, estriol and progesterone as active ingredients. These are materially different preparations, even though both pages discuss the uterine lining.

Neither record authenticates a particular prescription received by a patient. The capsule page does not establish that every other progesterone product has the same ingredients. Its suggestion of cream as an alternative for peanut allergy should not be adopted without a clinician and pharmacist considering both formulation and treatment purpose. Avoiding an ingredient and establishing the intended clinical effect are separate requirements. A prescription discussion should therefore identify which preparation is being proposed and why. This is particularly important when the provider presents a change in route as a way to address an ingredient concern while retaining another clinical purpose.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
Two product records should remain two product records — keep the exact product identity and its complete label together.

The protection claim is stronger than the evidence shown

Winona’s capsule discussion says its compounded progesterone cream protects the uterus as effectively as oral capsules. Its combined-cream page makes a related protection claim. The reviewed pages do not supply a comparative trial of the exact dispensed preparations establishing that equivalence.

The British Menopause Society’s protection guidance raises concerns about variable absorption of transdermal compounded progesterone and insufficient evidence of endometrial protection. This UK professional guidance is not an inspection of Winona’s pharmacy. It does, however, make clear why a convenient delivery format cannot settle the question. Alloy’s review provides a contrasting pill-based offer with different unresolved details.

Approval language needs to be read at the product level

One part of Winona’s FAQ describes all its hormone treatments as compounded. Another distinguishes FDA-approved tablets, capsules and patches from compounded creams. That internal difference means a general statement about the brand should not substitute for the actual product’s status.

FDA’s compounding explanation states that compounded medicines do not undergo its premarket approval review. A listed active ingredient, a pharmacy registration or a bioidentical description does not make an unapproved finished preparation approved. The systemic-estrogen guide returns to the clinical purpose, but the regulatory and formulation questions need their own clear answers alongside it.

Editorial illustration: an open reference book, a magnifying glass and a document.
Approval language needs to be read at the product level — follow the source behind a claim as well as the advertised description.

The reason for treatment comes before the convenience of one cream

The combined-cream page links estrogen symptom relief with progesterone’s protective role. That explanation should be tied to the actual estrogen exposure and history, not applied indiscriminately to all menopause prescriptions. FDA distinguishes systemic therapy from topical vaginal treatment, including separate product categories within those descriptions.

Our local-estrogen guide explains why a targeted vaginal treatment should not inherit a rule from a systemic plan. A body cream containing several hormones is also not automatically a low-dose local vaginal product. The person discussing care needs the preparation’s intended role made explicit, rather than relying on the fact that both are called creams.

The intake has practical access limits

The FAQ restricts hormone-treatment plans to ages 35–59 and lists the states and territories served. Those are platform conditions, not a personal medical clearance. Broad nationwide language elsewhere does not eliminate the need to confirm the listed jurisdiction and a physician’s assessment.

Winona describes asynchronous care without physician phone or video appointments. Message access is available continuously, but typical physician response is stated as twenty-four to forty-eight hours and may take longer. Gennev’s review examines a scheduled-visit alternative. That is a useful format comparison, without assuming that either arrangement is suitable for an urgent concern or demonstrates superior clinical outcomes.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
The intake has practical access limits — keep the exact product identity and its complete label together.

Monthly figures sit inside a renewing supply arrangement

The capsule starts at $39 per month and the combined cream at $89 per month. Those are separate starting offers, not a recommendation to purchase both or an established total for a patient. The FAQ says thirty-day supplies process every twenty-eight days and ninety-day supplies every eighty-four days.

The service does not bill insurance directly. Standard shipping is described as free; faster options carry charges. The FAQ permits cancellation and refund of an order only within its twenty-four-hour processing window, while future subscription cancellation is a separate account action. These distinctions should remain visible when comparing advertised monthly medicine figures with the actual recurring purchase.

A protection promise should not explain away bleeding

The cream’s advertised benefits include reduced irregular bleeding. That claim cannot identify the cause of bleeding in an individual using hormone treatment. ACOG advises evaluation of postmenopausal bleeding and abnormal changes during the transition, including changes that have more than one possible explanation.

The bleeding-and-plan guide focuses on obtaining an assessment rather than changing medicine independently. Winona’s offer is documented, but the appropriate preparation, its protective purpose and the response to a new concern require clinical explanations. An attractive single-product arrangement does not establish equivalent evidence, resolve an allergy question or verify that the symptoms being treated all share one cause.

Sources behind this article

Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.

  1. Winona: Progesterone CapsulesProvider oral-product listing; peanut oil and gelatin declared, starting price and broad cream-equivalence claims separated, no actual manufacturer or shipment authenticated · Checked 2026-09-29
  2. Winona: Estrogen Body Cream with ProgesteroneProvider compounded estradiol/estriol/progesterone cream and starting price; uterine-protection and safety language attributed, not independently demonstrated · Checked 2026-09-29
  3. British Menopause Society: Progestogens and Endometrial Protection (reviewed February 2026)UK professional guidance internally reviewed February 2026, May 2026 file version; compounded transdermal progesterone evidence and absorption limitations, no claim of testing a reviewed brand · Checked 2026-09-29
  4. Winona: Frequently Asked QuestionsProvider clinical and subscription conditions; age 35–59, listed jurisdictions, asynchronous care, differing approval descriptions, 28/84-day processing and 24-hour order window · Checked 2026-09-29
  5. FDA: Understanding the Risks of Compounded DrugsFederal regulatory explanation; compounded preparations are not FDA-approved, no inference about inspection or quality of a named pharmacy · Checked 2026-09-29
  6. FDA: Hormone Replacement Therapies Can Help Women with Bothersome Menopausal SymptomsCurrent federal categories and product-specific warning-change context; systemic estrogen and topical vaginal therapy distinguished, no class-wide warning conclusion · Checked 2026-09-29
  7. ACOG: Perimenopausal Bleeding and Bleeding After MenopauseUS specialty patient guidance reviewed February 2024; bleeding changes require professional assessment, not a site-generated workup or medication adjustment · Checked 2026-09-29
Read our editorial method →